Search
Search
Leinco Technologies
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Specificity: Clone CHK152 binds to and shows mechanisms of neutralizing of the Chikungunya E2 protein.
Endotoxin Level: <1.0 EU/µg as determined by the LAL method.
Purity: ≥95% monomer by analytical SEC and >95% by SDS Page.
Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage: Functional grade preclinical antibodies may be stored sterile as received at 2-8C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C. Avoid Repeated Freeze Thaw Cycles.
he E2 protein is a structural protein of the Chikungunya virus that is involved in viral entry and attachment to host cells. It is a glycoprotein with a molecular weight of approximately 50 kDa and is composed of three domains: domain A, domain B, and domain C. Domain A is responsible for receptor binding, while domain B is involved in the fusion of viral and host membranes. Domain C is a short cytoplasmic tail that interacts with the viral capsid protein. The E2 protein is located on the surface of the viral envelope and is responsible for the formation of the viral spikes that protrude from the virus surface. The E2 protein is an important target for the development of vaccines and antiviral drugs against Chikungunya virus.
仅用于科研。不用于诊断过程。未经明确授权不得转售。